Aujard Y, Brion F, Jacqz-Aigrain E, Kasse M C, Chretien P, Criqui C, Mathieu H
Neonatal Unit, Hopital Robert Debre, Paris, France.
Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):87-91. doi: 10.1016/0732-8893(89)90051-5.
A study of the pharmacokinetic parameters of cefotaxime (CTX) and desacetylcefotaxime (dCTX) in newborns was conducted; the former is commonly used for neonatal infections. The elimination half life of CTX correlated with gestational age (GA) and postnatal age (PNA). Elimination of dCTX was longer permitting a synergistic or additive effect with CTX against Gram-negative bacteria. CTX is indicated in the treatment of neonatal sepsis because of the increasing resistance of Escherichia coli to ampicillin and its good efficacy against group B streptococcus.
对新生儿头孢噻肟(CTX)和去乙酰头孢噻肟(dCTX)的药代动力学参数进行了研究;前者常用于新生儿感染。CTX的消除半衰期与胎龄(GA)和出生后年龄(PNA)相关。dCTX的消除时间更长,与CTX联合对革兰氏阴性菌有协同或相加作用。由于大肠杆菌对氨苄西林的耐药性增加,且CTX对B组链球菌疗效良好,因此CTX可用于治疗新生儿败血症。